Cellutech
A novel biomanufacturing platform — initially focused on human‑health compounds, now leading with an AI soil‑microbe product to reduce reliance on imported fertilisers.
A venture-stage stake in an established Australian programme.
Cellutech operates a novel biomanufacturing platform initially focused on producing high‑value bioactive compounds for human health. The company has since pivoted to lead with an AI soil‑microbe product, chosen for quicker market entry — with the potential to reduce Australia's reliance on imported fertilisers.
Field trials are under way. The platform retains broader optionality across human health, agriculture and nutraceutical applications, supported by onshore pilot‑scale biomanufacturing in Australia.
The company emerged from the UNSW Founders B10x accelerator programme and is led by Founder & CEO Joakim Wisting alongside a six‑person founding team. Proto Axiom holds a venture‑stage investment via the Bio 10x SAFE programme, signed in August 2024.
- Invested
- 2024
- Origin
- UNSW Sydney · B10x cohort
- Sector
- AgBio
- Modality
- AI soil‑microbe platform
Independently led; see the company website for the full team.
Where the programme is now, and what comes next.
- Now
- AI soil‑microbe pilot field trials under way. Onshore pilot‑scale biomanufacturing.